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Abstract
The main role of carbohydrates in the human body is to provide energy.
Carbohydrates should always be infused with PN (parenteral nutrition)
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Introduction – basics
Knowledge of the biochemistry and physiology of carbo-
hydratemetabolismisfundamentalinunderstandingthe
roleofcarbohydratesandtheircriticaluse.Themainrole
of carbohydrates in the human body is to provide energy.
Carbohydrates also occur in the human body bound to
proteins (proteoglycans), as amino sugars (glucosamine)
orinacomplexformascomponentsofmatrixstructures.
Carbohydrates are comprised of carbon (C) and water
(H2O), hence their name.
The regulation of the serum glucose level plays a central
role and is influenced by various factors: glucose intake
(enteral, parenteral); glucose oxidation in glycolysis or
pentosephosphate cycle; gluconeogenesis mainly in the
liver (but also occasionally in the kidneys); glucose ex-
change with glycogen stores in the liver and muscles.
Glycolysis
In aerobic conditions, glycolysis is the first step in the
process of glucose oxidation. In this 2 moles of pyruvate
(C3) are generated in cytosol from one mole of glucose
(C6) and 2 moles of adenosine triphosphate (ATP) are
released.
Under aerobic conditions, complete oxidation of the 2
molesofpyruvatethroughtheKrebscycleyields30moles
of ATP. Therefore, complete oxidation of one mole of
glucose to water and CO2 yields 36 moles of ATP and 2
moles of guanosine triphosphate (GTP). However, under
anaerobic conditions only 2 moles of ATP are generated,
and lactate is produced. Six moles of ATP are required to
synthesize one mole of glucose from lactate (Cori cycle),
so there is a net consumption of 4 moles of ATP. Humans
with normal metabolism utilise approximately 4–5 g/kg
body weight/day of glucose for glucose oxidation. Add-
itional glucose intake results in lipogenesis, with the
synthesis of triglycerides.
Gluconeogenesis and hepatic glucose
production
Glucose can be synthesised in the liver or, to a lesser
degree, in the kidneys. Substrates for gluconeogenesis
are lactate and pyruvate, which are derived from either
anaerobic glycolysis or the degradation of glucogenic
amino acids (e.g. alanine, valine) from the muscles.
Alanine can also be generated through the transfer of an
amino group from another amino acid (especially
branched-chain amino acids), to pyruvate.
The hepatic glucose production in a healthy person
amounts to a maximum of 2.2 mg/kg body weight/min
which is equivalent to 3.2 g of glucose/kg body
weight/day. This amount equals approximately 220 g of
glucose in a person weighing 70 kg. Gluconeogenesis is
an energy and oxygen consuming metabolic pathway,
whichaccountsfor50%ofthehepaticoxygenutilisation.
Invivo, gluconeogenesis and glycolysis take place simul-
taneously, and are arranged in a zonal fashion within the
liver. The hormonal situation of the body determines
which of these metabolic pathways prevail.
Hormonal regulation of carbohydrate
metabolism
Undernormalmetabolicconditions,carbohydratemetab-
olism is regulated predominantly by the interaction
between insulin and glucagon. Other important factors
in the regulation of carbohydrate metabolism are hor-
mones (epinephrine, cortisol) and cytokines (e.g. IL-6),
particularlyduringpost-aggressionmetabolism.Incertain
tissues,glucoseuptakeintothecellisinsulin-independent
(e.g.erythrocytes,renalmedulla,bonemarrow,leukocytes
and brain).
Insulin lowers the intracellular concentration of glucose
through genetic induction of key enzymes of glycolysis
and down-regulation of key enzymes involved in glucon-
eogenesis. Insulin/insulin+glucose have one effect, and
cAMP (acting as an intracellular agent for the glucagon)
or cAMP and corticosteroids have the opposite effect in
carbohydrate metabolism. Insulin also ensures that the
glycogen stores in the liver and muscle cells are replen-
ished. There is a simultaneous reduction in proteolysis
inperipheralmusclecells,whichprovidestheprecursors
forgluconeogenesis.Insulin,therefore,actsasananabol-
ic hormone.
Supply of carbohydrates
Carbohydrate application
• Carbohydrates should always be infused with PN (A).
Commentary
Carbohydrates, a key substrate in PN, can improve the
nitrogen balance by exerting a protein-saving effect [1],
[2],[3],[4],[5](Ib).Thiscanbepromotedmosteffectively
by combining the intake of amino acids with carbo-
hydrates, or of amino acids with carbohydrates and lipid
emulsions [5], [6], [7], [8], [9], [10]. Carbohydrate solu-
tions are not only used for nutritional purposes but also
for fluid replacement [11].
Types of carbohydrates to be
administered
• Glucoseshouldbeinfusedasastandardcarbohydrate
solution (C).
• The use of xylite is not generally recommended due to
controversial data (C).
• Fructose solutions should not be used for parenteral
nutrition (A).
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Thestandardparenteralcarbohydratesolutionisglucose.
Glucose is easy to measure in blood and urine for the
purpose of monitoring, and prevention of overdosage.
Fructose, an important carbohydrate in a regular diet,
can be partially metabolised in the body independent of
insulin. In the past, fructose was often used to provide
high-calorie nutrition to critically ill patients or diabetics,
to prevent the complication of hyperglycaemia without
insulin administration [12] (Ib). However, the use of
fructose to prevent complications is now less common
due to a decrease in the recommended carbohydrate or
energy intake [12], [13], [14], [15] (Ib). Life threatening
complications may arise in the event of a undiagnosed
hereditary fructose intolerance [16].
Xylite,asucrosesubstitute,canbemetabolisedindepend-
ent of insulin in the pentosephosphate cycle. However,
xylite administration results in lower concentrations of
glucose and insulin even during sustained endogenous
lipolysis due to its insulin-independent metabolism. The
effectsofxyliteadministrationonfunctionalproteinshave
been described, although not substantiated by clinical
outcome parameters. Xylite, therefore, is not recom-
mended in everyday use, due to dosage limitations and
time-consuming monitoring [12], [13], [14].
Carbohydrates and blood glucose level
• As a rule approximately 60% of non-protein energy
should be supplied as carbohydrates (C).
• The aim is to maintain normoglycaemia (A).
• Thebloodglucoselevelshouldbemaintainedbetween
80–110 mg/dL, if suitable to the overall clinical situ-
ation(A).Atleastaglucoselevelof<145mg/dLshould
be achieved, because levels above 145 mg/dL have
been associated with higher morbidity and mortality
(A).
Commentary
Hypoglycaemia can be prevented by intake of carbo-
hydratesinsituationswithreducedgluconeogenesis(e.g.
restricted liver function). In order to maintain nor-
moglycaemia, the exogenous intake should at least cor-
respond to the rate of the normal endogenous glucose
production of 2–3 g/kg body weight/day (1.4–2.1
mg/kg/min).Ifahigheramountofglucoseisinfused,the
proportion of glucose utilised for oxidation decreases,
whereas a higher proportion of glucose is stored as fat
[6], [17] (Ib).
Approximately 60% of non-protein energy should be sup-
pliedascarbohydrates,with4g/kgbodyweight/day(2.8
mg/kg/min) being the upper limit of supply. An intake of
3.0 and 3.5 g/kg body weight/day (2.1–2.4 mg/kg body
weight/min) is preferable. The endogenous glucose pro-
duction in critically ill patients is not reduced by a higher
infusion of exogenous carbohydrates or lipids [6], [18].
Inthesepatientstheriskofhyperglycaemiaisincreased.
Therefore,aninitiallowcarbohydrateinfusionrateof1–2
g/kg body weight/day should be selected for these or
other patients with a high risk of hyperglycaemia (dia-
betes, sepsis, steroid therapy) [19]. It should also be
noted that glucose tolerance decreases in older patients
[20].
The rate of glucose infusion should be monitored by
monitoring the blood glucose level, as procedures to
measureglucoseutilisation(indirectcalorimetry)arenot
routinely used. In postoperative intensive care patients,
maintenance of blood glucose levels between 80 and
110 mg/dL (6.1 mmol/L) were shown to be beneficial
with regards to mortality and morbidity, compared to
higher blood glucose levels [21], [22], [23]. A somewhat
higher threshold was set for blood glucose level (145
mg/dL;8.0mmol/L)inanotherpatientpopulationwhere
theoutcomeparameterwasICUmortality[24].Inastudy
of mixed surgical/medical patients, blood glucose levels
kept at approximately 140 mg/dL or lower by use of in-
sulin resulted in a significant improvement in mortality
and morbidity as compared to a group where patients
received insulin only after their blood glucose levels sur-
passed200mg/dL.Aretrospectiveanalysisofasubgroup
of this population showed that the lowest mortality oc-
curred when the blood glucose levels were kept between
80 and 99 mg/dL (4.4–5.5 mmol/L) [25]. A decrease in
mortality with strict maintenance of normoglycaemia in
criticallyillpatientsonlyoccurredwhentheintensivecare
treatmentperiodexceeded3days[26].Loweringofblood
glucose levels to between 80 and 110 mg/dL was also
associated with lower morbidity in critically ill patients
[26]. In an analysis of surgical patients, a blood glucose
level of over 110 mg/dL was associated with increased
mortality and morbidity, although this effect seemed to
be less marked in medical patients [22]. The positive ef-
fect on mortality and morbidity by maintenance of blood
glucose levels below 145 mg/dL is undisputed in all pa-
tients subjected to prospective randomised studies.
Hypoglycaemia, which occurs more often with the use of
intensive insulin therapy, requires frequent checks to
determine the correct insulin dose, which should be im-
plemented with the use of an established algorithm.
Moreover, hyperglycaemia was also associated with de-
terioration in various acute disorders such as cerebral
ischemia [27], [28], [29] or myocardial infarction [30],
[31], [32], irrespective of the presence of previously
diagnosed diabetes. It is likely that strict control of hyper-
glycaemia with insulin therapy will improve the outcome
and short-term morbidity in patients with such diseases.
However, there are no prospective studies addressing
this issue in these patient groups.
Contraindication–hyperglycaemia
• Hyperglycaemia may in addition to insulin infusion re-
quire a reduction, or even a temporary interruption, of
carbohydrate infusion (C).
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may be necessary. This demands strict monitoring of
blood glucose levels (B).
Commentary
The only contraindication for carbohydrate intake is
lasting hyperglycaemia with an insulin requirement of
more than 6 I.U./h. Patients with pre-existing diabetes
also require carbohydrates with simultaneous insulin in-
fusion in their PN. Insulin reduces blood glucose levels
through increased cellular glucose intake and glucose
turn-over. The effects of insulin may be greatly reduced
in certain disorders, such as diabetes mellitus, post-
operativeinsulinresistance,orsepsis.Inhyperglycaemia,
the amount of calories and carbohydrates should be re-
stricted (reduced to 2–3 g/kg body weight/day) and in-
sulin should be administered. Continuous intravenous
insulininfusionisnowpreferredinintensivecarepatients.
An intake of approximately 2–4 I.U./h is necessary as
part of PN after an initial bolus has been given. The
higher the insulin intake and lower the hyperglycaemia,
the more frequently the blood glucose levels should be
monitored. Initially, hourly to three-hourly checks are ne-
cessary (cf. chapter “Complications and monitoring”
http://www.egms.de/en/gms/2009-7/000076.shtml).
Notes
This article is part of the publication of the Guidelines on
Parenteral Nutrition from the German Society for Nutri-
tional Medicine (overview and corresponding address
under http://www.egms.de/en/gms/2009-7/000086.
shtml).
English version edited by Sabine Verwied-Jorky, Rashmi
Mittal and Berthold Koletzko, Univ. of Munich Medical
Centre, Munich, Germany.
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